This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Entera Bio (ENTX) and Merck & Company (MRK)

Tipranks - Tipranks - Tue May 12, 5:32AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Molina Healthcare (MOH), Entera Bio (ENTX) and Merck & Company (MRK).

Claim 55% Off TipRanks

Molina Healthcare (MOH)

Wells Fargo analyst Stephen Baxter assigned a Hold rating to Molina Healthcare yesterday and set a price target of $159.00. The company’s shares closed last Friday at $185.94.

According to TipRanks.com, Baxter is a 3-star analyst with an average return of 1.1% and a 47.5% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Tenet Healthcare. ;'>

Molina Healthcare has an analyst consensus of Hold, with a price target consensus of $165.23, which is a -14.4% downside from current levels. In a report issued on April 27, Truist Financial also maintained a Hold rating on the stock with a $180.00 price target.

See the top stocks recommended by analysts >>

Entera Bio (ENTX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Entera Bio, with a price target of $9.00. The company’s shares closed last Friday at $1.30.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.4% and a 54.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

Currently, the analyst consensus on Entera Bio is a Moderate Buy with an average price target of $9.00.

Merck & Company (MRK)

Wells Fargo analyst Mohit Bansal reiterated a Buy rating on Merck & Company today and set a price target of $145.00. The company’s shares closed last Friday at $111.38.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.9% and a 56.5% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $136.72, representing a 21.7% upside. In a report issued on May 9, TipRanks – PerPlexity also upgraded the stock to Buy with a $124.00 price target.

Read More on MOH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).